Pathological amino-acid substitutions in the amyloid precursor protein (APP) and chemical g-secretase modulators affect the processing of APP by the g-secretase complex and the production of the amyloid-beta peptide Ab42, the accumulation of which is considered causative of Alzheimer's disease. Here we demonstrate that mutations in the transmembrane domain of APP causing aggressive early-onset familial Alzheimer's disease affect both g-and e-cleavage sites, by raising the Ab42/40 ratio and inhibiting the production of AICD50-99, one of the two physiological APP intracellular domains (ICDs). This is in sharp contrast to g-secretase modulators, which shift Ab42 production towards the shorter Ab38, but unequivocally spare the e-site and APP-and Notch-ICDs production. Molecular simulations suggest that familial Alzheimer's disease mutations modulate the flexibility of the APP transmembrane domain and the presentation of its g-site, modifying at the same time, the solvation of the e-site.
T he main pathological hallmark of Alzheimer's disease (AD) is the formation of toxic amyloid fibres that progressively accumulate into plaques, which leads to degeneration of the neighbouring neuronal cells 1 . Further biochemical studies identified the main protein component of plaques to be a short fragment of amyloid precursor protein (APP), the 42-amino acid long peptide Ab42 (ref. 2) . Moreover, dominantly inherited mutations causing familial Alzheimer's disease (FAD) are found in APP as well as in the PSEN1 and PSEN2 (refs 3,4) genes encoding for the catalytic subunit of the g-secretase complex, an intramembrane-cleaving protease that cleaves APP in the plasma membrane and generates the Ab peptides 5 . Together, these findings clearly demonstrated the implication of APP, g-secretase and Ab in both the sporadic and genetic forms of AD. They further highlighted the g-secretase-dependent APP processing as an attractive target for drug development.
In addition to APP, g-secretase cleaves various other substrates regulating biological functions including development and stem cell differentiation. This unusual proteolytic complex indeed has an important role in cell signalling pathways by processing different type-I transmembrane cell receptors including the Notch receptors, the Insulin receptor and the Growth hormone receptor 6 . In the brain, it maintains synaptic contacts by regulating cleavage of neuronal adhesion molecules like Cadherins and Neurexins 7, 8 . With the continuously growing number of substrates the need for understanding the exact molecular mechanism of this particular proteolytic processing arises.
g-Secretase is composed of four subunits, presenilin (PS), Aph-1, Pen-2 and Nicastrin (NCT). The complex contains a total of 19 a-helices embedded in the membrane bilayer, which allows the overall structure to adopt different conformations upon binding with the substrate or different chemical compounds 9, 10 . Moreover, the catalytic aspartate residues (Asp257/385) in hPS1 are buried into the lipid bilayer and surrounded by hydrophobic helices and the electron microscopy density maps suggested the existence of two pores in the globular structure of g-secretase, which can explain the entrance of water molecules necessary for the hydrolysis of the peptide bond 11 . Yet, a rigorous biochemical characterization of g-secretase complexes with FAD mutations revealed that they all represent a loss of enzymatic function, but they ultimately lead to altered Ab production and elevated Ab42/ 40 ratio 12, 13 . Interestingly, FAD mutations in APP can show substrate cleavage patterns that differ from those of the mutations in g-secretase. In the processing of APP, its large extracellular domain is first removed by b-secretase in the vicinity of the plasma membrane (Fig. 1) . Gain-of-function mutations in this bsite cause elevated levels of total Ab 14 . g-Secretase processes the remaining 99-amino-acid APP-C-terminal fragment (APP-C99) at e-sites close to the inner layer of the membrane, and releases 49-and 50-amino-acid long APP intracellular domains (AICD50-99 and AICD49-99; Fig. 1 ). After this step, gsecretase sequentially continues to trim the residual transmembrane stub, finally producing Ab42, Ab40 and Ab38 peptides 15 (Fig. 1) . Mutations surrounding the e-sites either Figure 1 | Sequential proteolytic processing of APP by b-and c-secretases. Full-length APP is initially cleaved by b-secretase, liberating a soluble APPb (sAPPb) into the extracellular space. The remaining 99-amino-acid long transmembrane APP-C99 is further processed by g-secretase at e-sites, close to the inner layer of the membrane, releasing two APP intracellular signalling domains (AICDs) differing by one amino acid in length, AICD49-99 and AICD50-99. These products are in nearly equimolar ratio as depicted in the representative mass spectrometry AICD profile. Next, g-secretase continues to trim the residual membrane-embedded N-terminal fragment at g-sites, finally generating Ab peptides secreted into the extracellular space. In contrast to equimolar AICD production, mass spectrometric analysis of secreted Ab shows that Ab40 is in large excess when compared to the more amyloidogenic Ab42 directly involved in the pathogenesis of AD through the formation of Ab plaques.
increase the production of Ab42, which is more neurotoxic compared to the shorter and less fibrillogenic Ab40 or lead to elevated total amounts of the Ab product without affecting Ab ratios 13, 16 . Amino-acid substitutions in the g-site lead to high Ab42/40 ratios and are characterized by the most prominent and earliest phenotypes of FAD 17 .
Inhibiting the g-secretase activity to reduce Ab production is an attractive therapeutic strategy to treat AD. However, g-secretase inhibitors (GSIs) tested in clinical trials not only failed to meet their initial clinical endpoints, but also manifested severe off-target effects due to impaired Notch signalling, leading to gastrointestinal bleeding and increased risk of skin cancer 18 . Consequently, a concept of selective modulation of the g-secretase activity has emerged. A subset of non-steroidal antiinflammatory drugs (NSAIDs) were the first Notch-sparing small molecules shown to selectively lower Ab42 and subsequently raise Ab38 both in vitro and in vivo 19, 20 . These g-secretase modulators (GSMs) were initially shown to bind to APP, although some more recent studies demonstrated that they also can target g-secretase 21, 22 . Although the precise molecular mechanism of action remains poorly understood, a number of these molecules have advanced to clinical trials 23 .
In this report, we demonstrate that second generation GSMs, including the clinically tested E2012, effectively lower the production of toxic Ab42 without affecting the e-cleavage sites of both APP and Notch substrates. In contrast, we show that the T714I, V715A, V717F and L723P FAD-APP mutations in the transmembrane (TM) region block the production of AICD50-99, the 49-amino-acid long AICD, without affecting the total amount of AICD. Moreover, mutations T714I and V715A elevate the Ab42/40 and Ab38/40 ratios, in contrast to I716V, V717F and L723P for which these profiles were comparable to those obtained with wild-type APP. GSMs affect all mutants at their g-cleavage site, with the strongest effect on the Ab38/40 and Ab42/40 ratios in T714I and V715A, suggesting that these amino-acid substitutions are important for the generation of Ab42 and Ab38. In addition, we find that GSMs do not reverse the loss of AICD50-99 production caused by FAD mutations. We rationalize these findings using molecular dynamic simulations of the APP TM segment embedded in the lipid bilayer, and propose that FAD-APP mutants and possibly GSMs affect the g-cleavage site by changing the flexibility, tilt angle and position of the substrate in the membrane. GSMs fail to recover e-cleavage, most likely because they affect the substrate-enzyme interface at a position that is distant from the e-site and closer to the outer layer of the membrane. Finally, FAD mutants have altered solvation at the e-cleavage site, which can explain the different product lines generated after the first step of the processing of APP.
Results
GSMs affect the c-but not the e-cleavage of APP and Notch. We first investigated the effect of GSM-1 and E2012, two representative molecules of the two main classes of second generation GSMs: NSAID-based phenylpiperidine-type compounds and non-NSAID bridged aromatics, respectively (Fig. 2a ). Although these compounds have different structures, they both modulate g-secretase activity at low nanomolar concentrations in cells 24 . In enzymatic in vitro assays using highly purified g-secretase and recombinant APP-C100-Flag substrate, we first show that concentrations several fold higher than the cellular IC 50 values of GSM-1 and E2012 do not affect the overall amounts of Ab and AICD, when compared to control levels (Fig. 2b , upper panels and Supplementary Fig. S1 ). We next investigated in detail the effect of these molecules on all reaction products. For both compounds tested at 10 mM, immunoprecipitation with 4G8 antiAb antibody, combined with MALDI-TOF spectrometry (IP/MS) revealed a robust increase of Ab38/40 ratio, associated with a decrease in Ab42/40 ratio (Fig. 2b, middle panels) . At this concentration, GSM-1 showed a stronger effect than E2012 on Ab42/40 and Ab38/40 ratios, while both compounds lowered Ab43/40 ratio. IP/MS analyses of the C-terminal cleavage products revealed an unchanged equimolar production of the two AICDs (Fig. 2b, lower panels) . Together, these results clearly demonstrate that GSMs affect the APP g-cleavage sites, whereas they completely spare the e-sites. Because of the clinical relevance of GSMs and the Notch signalling pathway, we further investigated whether GSMs could interfere with the Notch intracellular domain (NICD) production. As shown in Fig. 2c , GSMs did not influence total NICD production and did not affect the NICD cleavage profiles. Our in vitro findings were further confirmed in cell-based assays. First, intracellular accumulation of endogenous g-secretase substrates APP-C83 and APP-C99, which is a common characteristic among known g-secretase substrates in response to g-secretase inhibition, was assessed in HEK293T cells stably overexpressing APP with the FAD Swedish mutation KM670/671NL. In contrast to the control GSI, 1 and 10 mM E2012 or GSM-1 did not affect the levels of APP-CTFs ( Supplementary Fig. S2a ). Next, treatments with E2012 and GSM-1 up to 1 mM in a cell-based luciferase assay, in which AICD generation correlates with increased luciferase expression and induced luminescence emission, did not result in a significant inhibition of AICD release ( Supplementary Fig. S2b ).
Additionally, the GSMs were tested in human lymphocytic leukaemia SUP-T1 cells constitutively producing NICD. In contrast to the GSI XIX that completely abolished NICD production, E2012 and GSM-1 did not affect NICD production at concentrations up to 10 mM ( Supplementary Fig. S3a ). These findings were confirmed in a cellular Notch-based assay in which a luciferase reporter system is directly placed under the control of NICD ( Supplementary Fig. S3b ), as well as in RPMI8402 (ref. 25) cells expressing a mutated Notch-1 receptor, which makes the receptor susceptible to constitutive cleavage by g-secretase in a ligand-independent manner ( Supplementary Fig. S3c ). In the latter two assays, E2012 and GSM-1 concentrations up to 1 mM did not affect NICD production. At 10 mM, E2012, but not GSM-1, significantly reduced NICD production in DL4-Hela/N1-Hela co-cultures by 55% (***Po0.001, Supplementary Fig. S3b ). Taken together, we conclude that E2012 and GSM-1 do not alter the Notch and APP e-site cleavage at concentrations as high as 10-fold cellular IC 50 . At higher concentrations (B100-fold cellular IC 50 ), only the non-NSAID-based compound E2012 can inhibit to some extent intracellular signalling of Notch and APP in cell-based assays.
APP mutations differentially alter c-and e-sites. APP mutations causing FAD can be grouped based on their localization at three different regions: at the b-secretase cleavage site, in close vicinity of the a-secretase cleavage site in the Ab region or in the transmembrane domain (TMD) of APP, between the g-and the e-sites (Fig. 3a, left) . These mutations differ not only by the onset of the disease (Fig. 3a, right) , but also by the molecular fingerprint of the produced Ab peptides. Indeed, the vast majority of mutations in the a-and b-sites lead to the overproduction of total Ab (mutations in the Ab region can also render the Ab42 peptide more fibrinogenic and prone to aggregation), while mutations in the transmembrane region seem to be linked to an elevated Ab42/ 40 ratio 13, 26 . As no information exists about how these mutations affect both the g-and e-cleavage sites in APP, and because AICD has been suspected to have a role in the pathogenesis of AD, we analysed Ab and AICD products generated from purified His6-tagged APP-C99 substrates carrying the FAD mutations listed in Fig. 3a . As shown in Supplementary Figs S4 and S5, we first verified that His6-and Flag-tagged substrates respond to GSM treatments in an identical manner, confirming that different tags (His6 or Flag) do not affect either the profiles of g-and e-site products ( Supplementary Fig. S4 ), or the overall production of Ab or AICD (Supplementary Fig. S5 ). Next, IP/MS analyses of the Ab and AICD profiles revealed that amino-acid substitutions clustered near the a-secretase (A692G, E693G and D694N) apparently do not alter the Ab or AICD profiles, when compared to the control WT APP-C99 ( Fig. 3b and Table 1 ). In striking contrast, T714I and V715A mutations close to the transmembrane g-cleavage site lead to drastically increased Ab42/40 and Ab38/40 ratios and to a total inhibition of the production of the shortest AICD50-99 (Fig. 3b,c and Table 1 ). Interestingly, mutations closer to the e-cleavage sites (I716V, V717F and L723P) are characterized by an intermediate phenotype as they do not alter Ab profiles, but clearly lower the production of AICD50-99 (below detection levels for V717F and L723P; Fig. 3b ,c and Table 1 ). Taken together, our data demonstrate that FAD-causing mutations in the transmembrane region of APP, but not close to the a-secretase site, affect both g-and/or e-sites (summarized in Table 1 ).
GSMs affect the c-but not the e-cleavage of APP. To better understand the molecular mechanism by which GSMs shift Ab production, as well as to verify whether GSMs can still lower Ab42 and have potential therapeutic benefits in patients with FAD, we decided to test GSM-1 on APP-C99 with FAD mutations. GSM-1 was chosen because it was more potent in our in vitro g-secretase assay, and also because this compound did not affect e-cleavage in all cell-based experiments. First, 10 mM GSM-1 did not affect the levels of total cleavage products (compare AICD and Ab levels in Supplementary Figs S4a and S5b), providing further evidence that GSMs do not modify the overall yield of g-secretase processing. Next, we found that GSM-1 conserved its Ab42-lowering and Ab38-raising properties on all tested mutant substrates (Fig. 4a) . However, GSM-1 did not influence the e-cleavage and none of the mutants tested recovered the wild-type phenotype of nearly equimolar production of AICD49-99 and AICD50-99 (compare AICD profiles in Figs 4b and 3c, and see estimations of AICD 49-99/AICD50-99 ratios in Table 2 ). Our findings provide new evidence that GSMs lower Ab42/40 ratio production by interfering with the g-site in APP substrates with FAD mutations, strongly suggesting that none of the substituted amino-acid residues are crucial for the GSM-dependent modulation of APP processing by g-secretase.
They further demonstrate that GSMs do not affect the e-cleavage site and thus fail to reverse the effects on AICD production of FAD-causing mutations in the transmembrane domain of APP (summarized in Table 2 ).
Structural changes in the TM domain of APP. To support our results mechanistically, we used molecular dynamic (MD) simulations to gain further insights into the structural and dynamic properties of the TMD of wild-type APP and three FAD mutants (T714I, V715A and V717F) in the membrane environment. These mutations were chosen because they affect either both g-and e-cleavage sites (T714I and V715A), or exclusively the e-site (V717F). As g-secretase activity assays performed with purified enzyme and APP-C99 substrate reconstituted in PC þ PE (phosphatidyl choline and phophatidylethanolamine) or PC alone revealed almost identical IP/MS profiles of Ab and AICDs ( Supplementary Fig. S6 ), the TM region of the APP-C99 NMR structure (PDB code 2LP1 (ref. 27)) was used and inserted into a palmitoyl oleoyl phosphatidyl choline (POPC) lipid bilayer (Fig. 5a) . Thus, MD simulations were carried out under physiological-like conditions (that is, pHB7, 1 atm, 300 K), mimicking as closely as possible the conditions of the g-secretase enzymatic assay used in our study. For all systems, the secondary structure of the APP fluctuated only marginally. Consistent with the NMR observations, the N terminus amphiphilic helix (Q686-N698) lies on the membrane surface, whereas a lysine belt (K687, K699 and K724-726) anchors the TMD and N terminus helices, respectively, in and onto the membrane (Fig. 5a ). During simulation, the helices tilted with respect to the membrane surface. We found that the V717F mutation affected the orientation of the TMD the most, tilting it by 45±5°, whereas the wild type and T714I and V715A mutants remained more vertical (36 ± 5°, 38 ± 3°and 36±3°, respectively) ( Fig. 5a and Supplementary Fig. S7a ). These mutations further shifted the TMD perpendicularly to the membrane surface. When measuring the position of the Ab42 cleavage site (that is, I712-A713 peptide bond), the T714I and V715A mutants shifted closer (2.9 ± 1.2 Å and 2.3 ± 0.9 Å, respectively) to the cytoplasmic interface compared to the WT, whereas V717F moved closer ( À 0.2 ± 1.3 Å) to the extracellular membrane layer (Fig. 5b) . The combined effect of shifting and tilting perturbations of the APP TMD is due to FAD mutations. This probably affects the presentation of the g-cleavage site at position 42 to the enzyme and correlates quantitatively with the changes in the Ab42/Ab40 ratio. Moreover, the flexibility of the transmembrane domain, which was estimated based on the local bending of the helix 28 , was much higher for the T714I and V715A mutants, specifically at the G 700 XXXG 704 XXXG 708 region (Fig. 5c ). Molecular docking and simulations of the GSM-1 compound suggest the same region to be the conserved drugbinding pocket for the wild-type and mutant APPs (Supplementary Fig. S7b ). In the drug-binding pocket, L701, G704 and G708 had the most direct interactions with GSM-1. Thus, the effect of GSM-1 on T714I and V715A FAD mutants might cause a reduction of their flexibility close to the g-site. For all three mutants, the hydration of the e-site at residue L720 significantly decreased compared to the WT (Fig. 5d ). In particular, for APP-WT, one water molecule is on an average within 3 Å of L720 backbone, the water coordination number drops to o0.5 Å for V715A, and to nearly zero for T714I and V717F. This effect is related to the different water permeation properties of the APP C terminus lysine belt combined with the perturbed helical orientation produced by the mutants. In summary, our data support a model in which structural changes, particularly the position of the g-cleavage site relative to the membrane surface, can potentially modulate Ab production. In this model the hydration of L720 can affect the e-cleavage site and the production of the two amyloid precursor protein intracellular domains potentially implicated in signalling pathways and in the pathogenesis of AD.
Discussion
Mutations in APP cause aggressive early-onset AD by triggering abnormal production, accumulation and aggregation of Ab peptides. The most severe pathological phenotype is observed for mutations occurring in the transmembrane region and in close vicinity of the Ab42 g-cleavage site, leading to elevated Ab42/40 and Ab38/40 ratios (Fig. 3) . Small chemical g-GSMs are known to lower Ab42 and raise Ab38, without affecting the overall production of the Ab peptides. In this study, we used second generation GSMs with a strong therapeutic potential (GSM-1 and E2012), in combination with APP substrates with FAD-causing mutations, to better understand the molecular mechanisms of the g-secretase-dependent, intramembrane and sequential cleavage of the substrate; to identify changes in APP cleavage profiles, potentially implicated in the pathogenesis of AD; and to further support the therapeutic potential of GSMs to safely treat sporadic as well as early-onset familial AD. We further demonstrate here that GSMs represent an attractive scaffold for structure-activity relationship design of potent disease-modifying drugs against AD. As they do not affect the processing of the Notch substrate (Fig. 2) , GSMs are expected to circumvent clinical side effects observed with GSIs and attributed to impaired Notch processing 18 . Moreover GSMs do not alter AICD production ( Fig. 2) and thus are not likely to influence the downstream cell signalling functions of APP, again underlying the huge therapeutic potential of these compounds in sporadic AD cases. Additionally, our results confirm altered g-site Ratios are estimated from peak intensities determined by MALDI-TOF analysis with respect to Fig. 3 .
processing in APP T714I and V715A mutations 13 , associated with an increase of Ab42/40 and Ab38/40 ratios and demonstrate that mutations located in close vicinity to the g-site do impede the production of the shorter e-site counterpart AICD50-99. Our novel findings shed light on the effect of GSMs on the generation of all Ab and AICD species from APP-WT and APP-FAD. In our study, we have further investigated the effect of GSMs on the g-and e-site APP cleavage products. Our results show that none of the amino-acid residues of APP-WT causing FAD when mutated are critically implicated in the mechanism of action of GSMs in shifting the production from Ab42 to Ab38. Next, we demonstrate that GSMs are not involved in the first step of the sequential proteolytic model 15 because they do not modulate the e-site products (AICD50-99 and AICD49-99) of the enzymatic reaction. Interestingly, mutations T714I and V715A display the strongest phenotype at both g-and e-sites, with highest Ab42/40 and Ab38/40 ratios (Table 1) . Moreover, these mutations lead to the production of only one detectable AICD, suggesting a putative role of AICD in AD pathogenesis. These results might be explained with the sequential cleavage model of APP-CTF, in which the generation of Ab40 is dependent on the AICD50-99, while Ab42/38 is linked to AICD49-99 (ref. 15) . Based on this model, reduced AICD50-99 (as observed for some FAD mutants) is expected to be associated with less Ab40 and more Ab42/38, thus increasing the pathogenic ratio of Ab42/40. The combination of higher Ab42/40 ratio and the loss of AICD50-99 can explain the extreme aggressiveness of these APP mutations with regard to the onset of the disease. GSMs were still potent at the g-site of mutated APP substrates (Fig. 4) , as expected from molecular docking and simulations suggesting the G 700 XXXG 704 XXXG 708 region as a possible GSM-binding pocket ( Supplementary Fig. S7b ). GSMs have also been shown to target PS1-NTF 9, 22, 29 , supporting the hypothesis that these compounds could bind at the interface between APP-C99 and the substrate-docking site of g-secretase. Moreover, the region between g-and e-sites on APP-CTF has been proposed to be a binding domain for PS1-NTF 30 , and peptides mimicking this domain can selectively block Ab production, sparing Notch processing 31 . Together, these findings clearly demonstrate that GSMs can be used for the treatment of patients with both sporadic and genetic forms of AD. Rationalizing these results with structural models based on molecular simulations of wild-type and mutant APP substrates, we propose that the observed effects on Ab and AICD production can be triggered by combined changes in the flexibility, tilting angle and positioning of both g-and e-sites in the membrane, along with the hydration levels at the e-sites. Such structural changes, by potentially modifying the presentation of the substrates to the enzymatic complex, might affect the g-secretase cleavage specificity. Consistent with this model, the elevated Ab38/40 ratio observed in mutants T714I and V715A can be explained by the vertical shift of the helix in the membrane bilayer, with the consequent presentation of position 38 instead of 40 to the g-secretase cleavage site. The observed vertical shift in mutants (B2.5 Å) is in fact associated with a tilting of half of a helix turn (that is, displacement of two amino acids). Interestingly, Ab38 and Ab42 have been proposed to originate from the same sequential processing pathway, starting at the e-position 48, and directly linked to AICD49-99 production 15 . Consistent with this sequential model, we propose that the conformational changes in the T714I and V715A substrates, associated with reduced AICD50-99 levels, explain the preferential Ab38 and Ab42 production observed with these mutants. Interestingly, and apparently in contrast to the sequential cleavage model, the V717F and L723P mutants, although characterized by reduced AICD50-99 levels, do not show modifications in their Ab profiles. This observation may reflect the existence of two or more different pathological molecular explanations, classifying FAD forms in different categories.
The nearly complete loss of AICD50-99 production in mutants T714I, V715A, V71F and L723P, can plausibly be attributed, according to our model, to higher solvation states around positions 49 and 50, with the latter becoming more exposed to water molecules. One can speculate that the increased water accessibility to the leucine 49 may favour the cleavage at this position, or inhibit the cleavage at valine 50 by preventing the interaction at position 50 of APP-C99 with the hydrophobic transmembrane domain 1 of the g-secretase catalytic component PS1.
Possibly affecting the positioning of both APP g-and e-sites in the membrane, cholesterol and the dimerization of APP have recently been proposed to modulate the processing of APP-TMD 32, 33 . Although preliminary, our results ( Supplementary Fig.  S8 ) suggest that when APP does not interact physically with cholesterol molecules in a membrane made of POPC þ 15% cholesterol, the dynamic properties of its TMD, including the position of the Ab42 cleavage site, are the same as those of APP inserted into a pure POPC membrane. Further investigation is required to challenge this hypothesis, and examine whether both cholesterol levels and APP dimerization parameters can affect the dynamic properties of wt or FAD-APP TMDs.
Together, our data reported here provide new insights into the therapeutic potential of chemical g-secretase modulators. They are further expected to improve our current understanding of the pathological mechanism of FAD.
CGenFF and ParamChem 0.9.6 (ref. 37 ). All MD simulations were performed using NAMD 2.8 engine, with the CHARMM27 force field, including CMAP corrections for the protein and CHARMM36 for the POPC membrane 38, 39 . TIP3P water parameterization was used to describe the water molecules. The periodic electrostatic interactions were computed using the particle-mesh Ewald (PME) summation with a grid spacing o1 Å. All systems were equilibrated for 30 ns at 300 K. Free molecular dynamics were performed up to 100 ns with a 2 fs integration time step using the RATTLE algorithm applied to all bonds. Constant temperature (300 K) was imposed by using Langevin dynamics, with damping coefficient of 1.0 ps. Constant pressure of 1 atm was maintained with a Langevin piston dynamics, 200 fs decay period and 50 fs time constant.
GSM-1 was docked on WT and APP mutants using SWISSDock 40, 41 and BSP-SLIM 42 ; independently both approaches produced similar poses. As these algorithms do not account for the presence of the membrane, we discarded all unphysical docking poses, for example, the GSM-1 hydroxyl being buried in the hydrophobic membrane core. The conformation with the lowest energy was then selected for each system.
